• CPT: Patent Trial and Appeal Board, including institution of proceedings, Fintiv/NHK and related procedures Patent-eligible subject matter Injunctive relief against patent infringers Standard Essential Royalty Act, to establish a patent licensing royalty rate-setting judicial panel disadvantageous to patent owners and favorable to patent infringers H.R. 3535 (Advancing Americas Interest Act) to disadvantageously change U.S. firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods S. 2321/H.R. 5893 (Commerce-Justice-Science Appropriations, FY24) report language to erect barriers to Sec. 337 USITC remedies to block importation of U.S. patent-infringing goods Proposals to misuse Bayh-Dole Acts march-in against patent ownership rights based on product price Unilateral changes to Dept. of Energy funding agreements requiring headquarters review of any licensing agreement, undermining the Bayh-Dole Act Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights (Docket No. PTO-P-2022-0025) Request for Comments Regarding Joint USPTO-FDA Collaboration Initiatives (Docket No. PTO-P-2022-0037) Federal position on proposal at World Trade Organization to waive intellectual property protections due under Trade-Related Aspects of Intellectual Property Rights Agreement with regard to COVID-19-related inventions Comments on U.S. International Trade Commission Investigation No. 332-596, COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities Comments on advance notice of proposed rulemaking, Changes Under Consideration to Discretionary Institution Practices, Petition Word-Count Limits, and Settlement Practices for America Invents Act Trial Proceedings Before the Patent Trial and Appeal Board (Docket No. PTO-P-2020-0022) S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) Comments related to National Institutes of Health, Workshop on Transforming Discoveries into Products: Maximizing NIHs Levers to Catalyze Technology Transfer S. 2140 (Patent Eligibility Restoration Act (PERA)) Mandatory customer stay that deprives patent owners of the ability to enforce their patent rights against all parties such as through injunctive relief and that would unfairly protect direct and contributory patent infringers, including large retail corporations Defending American Patents Act, which would punish U.S. patent owners with the loss of six years of patent protection for asserting their patent in a foreign court against an American patent infringer H.R. 5475 (Preventing Adversarial Patents Act), which would radically change from the hallmark of merit-based U.S. patent issuance, by adding denial or unenforceability of patents based on certain characteristics of the patentee Comments on U.S. Patent & Trademark Office, Joint Collaboration Initiative Regarding Standards (Docket No. PTO-C-2023-0034) Digital copyright piracy, site-blocking injunction National Institute of Standards and Technology, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No. NIST-2023-0008) Comments to U.S. Patent & Trademark Office, regarding WIPO IGC Negotiations on Genetic Resources and Associated Traditional Knowledge (Docket No.: PTO-C-2023-0019) H.R. 7476 (Countering Communist China Act) intellectual property provisions H.R. 8134 (Restoring Americas Leadership in Innovation Act) Comments to USPTO on Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace (Docket No. PTO-C-2024-0004) Comments to USPTO on Patent Trial and Appeal Board Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement (Docket No. PTO- P-2023-0048) Leadership in Critical and Emerging Technologies (CET) Act to expedite CET patent examination S. 1956 (Invent Here, Make Here Act)
• RES: H.J. Res. 27/S.J. Res. 7 (Congressional Review Act disapproval of the Waters of the United States (WOTUS) rule issued by the Biden Environmental Protection Agency and the Corps of Engineers) H.R. 4394 (Energy and Water Development and Related Agencies Appropriations Act) provisions related to proscriptions on the Biden administrations Revised Definition of Waters of the United States
• S. 1108/H.R. 7035 (Death Tax Repeal Act) Confiscatory tax schemes, e.g., capital gains tax rate increase, taxing trusts, step up in basis repeal, taxing unrealized assets at death (double death tax) Provisions of the Tax Cuts and Jobs Act of 2017: Full and immediate expensing (Section 168(k) of the Internal Revenue Code), full deductibility of research & development costs (Section 174), deductibility of depreciation and amortization costs (Section 163(j))
• Antitrust Consumer welfare standard Federal Trade Commission regulatory excesses, such as antitrust merger reviews and challenges H.J. Res. 30/S.J. Res. 8 (Congressional Review Act disapproval of the ESG investment rule for employee retirement savings benefits, submitted by the Department of Labor relating to "Prudence and Loyalty in Selecting Plan Investments and Exercising Shareholder Rights) Draft Merger Guidelines for Public Comment (FTC-2023-0043-0001) Notice of Proposed Rulemaking: Premerger Notification; Reporting and Waiting Period Requirements (RIN No. 3084-AB46) Oversight of U.S. Department of Justice Antitrust Division and Federal Trade Commission S. 148 (Stop STALLING Act) S. 142 (Preserve Access to Affordable Generics and Biosimilars Act) S. 150 (Affordable Prescriptions for Patients Act)
• Price controls proposals regarding pharmaceuticals or other medical goods or services, including direct government price-setting, reduced reimbursement rates, and restrictions on beneficiary choice and plan or provider competition in government health programs or private insurance plans H.R. 485 (Protecting Health Care for All Patients Act) S. 1246/S. 1264 (Strengthening Medicare and Reducing Taxpayer (SMART) Prices Act) Senate HELP Committees 2023 Reauthorization of the Pandemic and All-Hazards Preparedness Act, Sec. 601, BARDA reasonable pricing requirements, and Sec. 602, CDC reasonable pricing requirements, other contemplated "reasonable pricing price controls and patent prize schemes Repeal of Inflation Reduction Act (IRA), Sec. 5000D, drug price controls product price negotiation and 95% inflation penalty and IRA implementation
• H.R. 1 (Lower Energy Costs Act) H.R. 1615(Gas Stove Protection and Freedom Act) H.R. 1640(Save Our Gas Stoves Act)
• Republican Study Committee FY24 budget proposal H.R. 2811 (Limit, Save, Grow Act) debt limit and offsets H.R. 3746 (Fiscal Responsibility Act) debt limit and offsets Republican Study Committee FY25 budget proposal
• H.R. 277 (REINS Act) regulatory reform to major rule H.R. 288(Separation of Powers Restoration Act) Administrative Procedure Act reforms to statutory interpretation H.R. 6758 (Defense of Property Rights Act) establishing a uniform, more efficient process for protecting property owners' Fifth Amendment rights H.R. 7455 (Sunset Act) regulatory reform for automatic expiration of rules and regulations after 10 years, unless Congress extends it

Duration: June 15, 2017 to present

General Issues: Copyright/Patent/Trademark, Real Estate/Land Use/Conservation, Taxation/Internal Revenue Code, Labor Issues/Antitrust/Workplace, Health Issues, Energy/Nuclear, Budget/Appropriations, Government Issues, Medicare/Medicaid, Clean Air & Water (Quality), Economics/Economic Development, Communications/Broadcasting/Radio/TV, Roads/Highway, Telecommunications, Trade (Domestic & Foreign), Small Business

Spending: about $646,750 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2017: U.S. Senate, House of Representatives, Patent & Trademark Office (PTO), U.S. International Trade Commission (ITC), Federal Trade Commission (FTC), Justice - Dept of (DOJ), Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), Natl Institute of Standards & Technology (NIST), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), U.S. Trade Representative (USTR), Army - Dept of (Corps of Engineers), Commerce - Dept of (DOC), Intl Trade Administration (ITA), Internal Revenue Service (IRS)